Artiva Biotherapeutics, Inc. ARTV
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is an immunology/inflammation drug developer. Its lead program, AlloNK (AB-101) plus rituximab, is in Phase 2 for Refractory rheumatoid arthritis (lead); also Sjögren’s disease, systemic sclerosis, idiopathic inflammatory myopathies. Its next catalyst on record is AlloNK: Initiation of registrational Phase 3 trial in refractory RA (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: AlloNK — Initiation of registrational Phase 3 trial in refractory RA (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AlloNK + rituximab, planned registrational Phase 3 (approx. 150 patients) | Refractory RA (inadequate response to 2+ b/tsDMARD classes) | cell therapy | Phase 3 |
| AlloNK (AB-101) + rituximab, Phase 2a basket trial | Refractory RA, SjD, IIM, SSc | cell therapy | Phase 2 |
| AlloNK + mAb, investigator-initiated basket trial | B-cell driven autoimmune diseases | cell therapy | Phase 2 |
| AlloNK + rituximab, Phase 1/2 trial | Relapsed/refractory B-cell non-Hodgkin lymphoma (completed July 2025; long-term follow-up discontinued) | cell therapy | Phase 2 |
Recent results and decisions
- May 8, 2026positive Phase 2a basket: 5/7 (71%) refractory RA patients with 6-month follow-up achieved ACR50, no CRS/ICANS, no AE-related discontinuations.
Five of seven patients (71%) with six months of follow-up in the company-sponsored Phase 2a basket trial achieved an ACR50 response.
Filing - May 8, 2026n/a FDA alignment on a single ~150-patient randomized Phase 3 registrational trial (AlloNK + rituximab vs rituximab; primary endpoint ACR50 at 6 months).
U.S. Food and Drug Administration (FDA) alignment on a single registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six months as the primary endpoint
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.